β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids Farnesoid X Receptor and Constitutive Androstane Receptor

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Aug 14

PMID 30100908

Citations 9

Authors

Thomas Klag

Maria Thomas

Dirk Ehmann

Lioba Courth

Daniela Mailander-Sanchez

Thomas S Weiss

Rania Dayoub

Kerstin Abshagen

Brigitte Vollmar

Wolfgang E Thasler

Eduard F Stange

Christoph P Berg

Nisar P Malek

Ulrich M Zanger

Jan Wehkamp

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Knowledge about innate antimicrobial defense of the liver is limited. We investigated hepatic expression and regulation of antimicrobial peptides with focus on the human beta defensin-1 (hBD-1).

Methods: Radial diffusion assay was used to analyze antimicrobial activity of liver tissue. Different defensins including hBD-1 and its activator thioredoxin-1 (TXN) were analyzed in healthy and cholestatic liver samples by qPCR and immunostaining. Regulation of hBD-1 expression was studied and using bile duct-ligated mice. Regulation of hBD-1 bilirubin and bile acids (BAs) was studied using siRNA.

Results: We found strong antimicrobial activity of liver tissue against . As a potential mediator of this antimicrobial activity we detected high expression of hBD-1 and TXN in hepatocytes, whereas other defensins were minimally expressed. Using a specific antibody for the reduced, antimicrobially active form of hBD-1 we found hBD-1 in co-localization with TXN within hepatocytes. hBD-1 was upregulated in cholestasis in a graded fashion. In cholestatic mice hepatic AMP expression (Defb-1 and Hamp) was enhanced. Bilirubin and BAs were able to induce hBD-1 in hepatic cell cultures . Treatment with siRNA and/or agonists demonstrated that the farnesoid X receptor (FXR) mediates basal expression of hBD-1, whereas both constitutive androstane receptor (CAR) and FXR seem to be responsible for the induction of hBD-1 by bilirubin.

Conclusion: hBD-1 is prominently expressed in hepatocytes. It is induced during cholestasis through bilirubin and BAs, mediated by CAR and especially FXR. Reduction by TXN activates hBD-1 to a potential key player in innate antimicrobial defense of the liver.

Citing Articles

What defines a healthy gut microbiome?.

Van Hul M, Cani P, Petitfils C, de Vos W, Tilg H, El-Omar E Gut. 2024; 73(11):1893-1908.

PMID: 39322314 PMC: 11503168. DOI: 10.1136/gutjnl-2024-333378.

Two intestinal microbiota-derived metabolites, deoxycholic acid and butyrate, synergize to enhance host defense peptide synthesis and alleviate necrotic enteritis.

Kim D, Liu J, Whitmore M, Tobin I, Zhao Z, Zhang G J Anim Sci Biotechnol. 2024; 15(1):29.

PMID: 38429856 PMC: 10908072. DOI: 10.1186/s40104-024-00995-9.

Bile duct ligation differently regulates protein expressions of organic cation transporters in intestine, liver and kidney of rats through activation of farnesoid X receptor by cholate and bilirubin.

Hong S, Li S, Meng X, Li P, Wang X, Su M Acta Pharm Sin B. 2023; 13(1):227-245.

PMID: 36815051 PMC: 9939304. DOI: 10.1016/j.apsb.2022.06.010.

Diclofenac Disrupts the Circadian Clock and through Complex Cross-Talks Aggravates Immune-Mediated Liver Injury-A Repeated Dose Study in Minipigs for 28 Days.

Selvaraj S, Oh J, Yoon S, Borlak J Int J Mol Sci. 2023; 24(2).

PMID: 36674967 PMC: 9863319. DOI: 10.3390/ijms24021445.

Differences of core genes in liver fibrosis and hepatocellular carcinoma: Evidence from integrated bioinformatics and immunohistochemical analysis.

Li Y, Yuan S, Yin J, Yang K, Zhou X, Xie W World J Gastrointest Oncol. 2022; 14(7):1265-1280.

PMID: 36051101 PMC: 9305567. DOI: 10.4251/wjgo.v14.i7.1265.

References

Gomes A, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M . Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics. 2009; 10(4):579-99. DOI: 10.2217/pgs.09.7. View

Wiest R, Lawson M, Geuking M . Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2013; 60(1):197-209. DOI: 10.1016/j.jhep.2013.07.044. View

Hirschfield G, Mason A, Luketic V, Lindor K, Gordon S, Mayo M . Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2014; 148(4):751-61.e8. DOI: 10.1053/j.gastro.2014.12.005. View

Jansen P . The pathophysiology of cholestasis with special reference to primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000; 14(4):571-83. DOI: 10.1053/bega.2000.0104. View

Huang W, Zhang J, Chua S, Qatanani M, Han Y, Granata R . Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci U S A. 2003; 100(7):4156-61. PMC: 153064. DOI: 10.1073/pnas.0630614100. View

Klein M, Thomas M, Hofmann U, Seehofer D, Damm G, Zanger U . A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and excretion gene expression and activity in primary human hepatocytes and HepaRG cells. Drug Metab Dispos. 2014; 43(2):273-83. DOI: 10.1124/dmd.114.060962. View

Strnad P, Schwarz P, Rasenack M, Kucukoglu O, Habib R, Heuberger D . Hepcidin is an antibacterial, stress-inducible peptide of the biliary system. PLoS One. 2011; 6(1):e16454. PMC: 3025980. DOI: 10.1371/journal.pone.0016454. View

Schroeder B, Wu Z, Nuding S, Groscurth S, Marcinowski M, Beisner J . Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature. 2011; 469(7330):419-23. DOI: 10.1038/nature09674. View

Kandel B, Thomas M, Winter S, Damm G, Seehofer D, Burk O . Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARα in primary human hepatocytes. Biochim Biophys Acta. 2016; 1859(9):1218-1227. DOI: 10.1016/j.bbagrm.2016.03.007. View

10.

Fischer S, Beuers U, Spengler U, Zwiebel F, Koebe H . Hepatic levels of bile acids in end-stage chronic cholestatic liver disease. Clin Chim Acta. 1996; 251(2):173-86. DOI: 10.1016/0009-8981(96)06305-x. View

11.

Nevens F, Andreone P, Mazzella G, Strasser S, Bowlus C, Invernizzi P . A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. 2016; 375(7):631-43. DOI: 10.1056/NEJMoa1509840. View

12.

De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L . Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2013; 59(5):1738-49. DOI: 10.1002/hep.26695. View

13.

Liu Y, Binz J, Numerick M, Dennis S, Luo G, Desai B . Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003; 112(11):1678-87. PMC: 281645. DOI: 10.1172/JCI18945. View

14.

Harada K, Nakanuma Y . Biliary innate immunity: function and modulation. Mediators Inflamm. 2010; 2010. PMC: 2926654. DOI: 10.1155/2010/373878. View

15.

Ghonem N, Assis D, Boyer J . Fibrates and cholestasis. Hepatology. 2015; 62(2):635-43. PMC: 4515188. DOI: 10.1002/hep.27744. View

16.

Nies A, Koepsell H, Winter S, Burk O, Klein K, Kerb R . Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009; 50(4):1227-40. DOI: 10.1002/hep.23103. View

17.

Thomas M, Burk O, Klumpp B, Kandel B, Damm G, Weiss T . Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARα). Mol Pharmacol. 2013; 83(3):709-18. DOI: 10.1124/mol.112.082503. View

18.

Seki E, Schnabl B . Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2011; 590(3):447-58. PMC: 3379693. DOI: 10.1113/jphysiol.2011.219691. View

19.

Sung J, Costerton J, Shaffer E . Defense system in the biliary tract against bacterial infection. Dig Dis Sci. 1992; 37(5):689-96. DOI: 10.1007/BF01296423. View

20.

Wu T, Zhang Z, Liu B, Hou D, Liang Y, Zhang J . Gut microbiota dysbiosis and bacterial community assembly associated with cholesterol gallstones in large-scale study. BMC Genomics. 2013; 14:669. PMC: 3851472. DOI: 10.1186/1471-2164-14-669. View